R&D Productivity Longitudinal Study

Catenion co-founder and senior partner Markus Thunecke presents the main findings of Catenion’s R&D productivity longitudinal study. Catenion began systematically analyzing the R&D productivity of pharma companies about ten years ago because good analysis was not available: most companies only tracked approvals of new molecular entities, and everyone claimed to beat the average, which is mathematically impossible.
Methodology: R&D productivity has R&D spending, adjusted for the cost of M&A, as the denominator, and the present value of the pipeline plus the value of products launched in the last eight years (long-term ratio), or the NPV of the pipeline alone (short-term ratio), as the numerator. Corporate growth is tracked through sales, EBITDA and market cap for the 30 largest public biopharma companies.
Performance clusters:

  • Novo Nordisk, the lone winner: always in the top five thanks to a relentless focus on metabolic disease and GLP-1 medicines, and driven for many years by internal research rather than deals.
  • Turnaround champions AstraZeneca and Lilly: both started as typical big pharma underperformers facing patent cliffs. AstraZeneca shows the power of portfolio decision-making (its 5R framework) combined with focused internal and external innovation. Lilly changed its approach to R&D to bring more accountability and nimbleness by mimicking biotech-like structures and governance.
  • Companies that benefited from recent and not always sustainable upsurges: Pfizer (COVID), Daiichi Sankyo (antibody-drug conjugates and deals) and Eisai (Alzheimer’s antibodies).
  • Biogen and Gilead, which failed to scale up their once-strong R&D and corporate growth outperformance.
    Key drivers of R&D productivity:
  • Size: above a critical mass of roughly a 1 to 2 billion R&D budget, size becomes a burden, and mid-sized companies are over-represented in the top 10.
  • Focus: doubling down on complex scientific areas beats spreading resources thinly.
  • Therapeutic area mix: oncology has an intrinsic advantage (spin-off indications after proof of concept), while CNS and cardiovascular correlate negatively with productivity.
  • Key high-value assets: the best thing for R&D productivity is a pipeline in a product, provided it is recognized early and developed broadly.
  • Internal versus external innovation: contrary to the “search and develop” narrative, internal R&D is behind the performance of many top-10 companies, and the best performers run hybrid models in which strong internal capabilities let them pick external winners early.
    Conclusion: outperformance over long periods is possible, even for big pharma coming back from underperformance. The biggest challenge is to sustain it without falling into bureaucracy and poor ownership, and investing in the quality of decision-making is probably the quickest way to improve R&D productivity.

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions. Learn more and manage your cookie settings here.

Catenion Arno Heuermann 2

Arno Heuermann

Arno Heuermann is a founding Partner of Catenion who lives in Berlin, Germany. Arno has ten years of experience as CEO and COO. He has managed companies in Germany, France and Luxemburg.

While working on his degrees, Arno founded a technical engineering office in 1994. He continued to follow the entrepreneurial path in 1998 by founding Biopsytec GmbH, a DNA diagnostics company focused on agriculture, heading the company for more than five years as Managing Director.

In 1999, he co–founded Epigenomics AG, a public biotech company focused on DNA methylation, later remaining as an advisor and member of the firm’s Supervisory Board.

In August 2000, Arno orchestrated the founding and financing of Biopsytec Holding AG, thus merging Genious SA and the QTL AG and Biopsytec GmbH. He managed Biopsytec Holding AG for the next three years before helping launch Catenion in 2003. Since that time, he has been Catenion’s chief operating officer.

Arno holds a diploma degree in process engineering from the Technical University of Applied Sciences in Berlin. In addition, Arno attended the Berlin business school for Industrial Engineering and Management.

He is experienced in the diverse practices of patent management and has made numerous successful inventions.

Arno Heuermann is married and has two children. He is a lover of classical music, country life and horseback riding.

Catenion Matthias Krings

Dr. Matthias Krings

Matthias Krings is a founding Partner of Catenion.

He has worked for international pharma, biotech and medtech organizations on a variety of topics. Matthias works with clients on developing corporate and R&D strategies, identifying new areas of opportunity, tailoring asset and company searches for BD&L and M&A, maximizing the value of existing assets through therapeutic expansion, and prioritizing R&D portfolios. Matthias is also responsible for the creation and delivery of bespoke client education programs in the Catenion Academy.

Before co-founding Catenion in 2003, Matthias was a consultant at Mercer Management Consulting (now Oliver Wyman) and later joined a strategy consulting boutique, Theron.

Matthias holds a diploma and a doctorate degree in Biology from the Ludwig-Maximilians University in Munich. His PhD work was supported by a scholarship from the Boehringer Ingelheim Fonds, Foundation for Basic Research in Medicine. Matthias made significant scientific contributions to the field of human evolution, published in Krings et al., Cell 1997: Neandertal DNA Sequences and the Origin of Modern Humans. His PhD supervisor Svante Pääbo was awarded the Nobel Prize in Physiology or Medicine in 2022 “for his discoveries concerning the genomes of extinct hominins and human evolution”.

Matthias lives in Munich. He enjoys cooking, gardening, water sports and traveling.

Catenion Christian Elze

Christian Elze

Christian Elze is a founding partner of Catenion and has been developing the company’s business in Japan since 2008. He holds a BSc from the London School of Economics and an MBA from Columbia University.

As of January 2024, Christian is moving to a role of Senior Partner Emeritus; while continuing to look after selected clients and projects, he is reducing his time spent with the company; he has accepted positions as a member of the Scientific Advisory Board of Recordati in Milan and a Board Observer of Pangea Biomed in Tel Aviv.

Christian is working with companies, universities and governments in the field of biomedical innovation. In his work, Christian is focusing on how emerging technologies and translational research are re-shaping the respective roles of funding agencies, investors, biopharma companies and academia in the research and development of new drugs.

Besides his consulting work, Christian frequently speaks about Emerging Technologies, Healthcare Reform, Pricing & Reimbursement,  Biomedical Innovation, as well as Translational Research at industry conferences and universities in Japan, the US and Europe.

Christian is a fluent speaker of English, French, German, Italian, Portuguese, Russian and Spanish and divides his time between London and Alto Paraiso de Goias in Brazil.

Catenion Markus Thunecke compressed

Dr. Markus Thunecke

Markus has written several Catenion Commentaries including “Risk Profiles of Corporate Portfolio Strategies” as well as “Elements of Winning Strategies in R&D”, “Recombinant Innovation Management (RIM) – How to Stimulate Breakthrough Innovation within Large R&D Organisations”, “Recombinant Portfolio Management – Recognising and Enabling Innovation”. He also co–authored “Zero Base R&D” and “The Challenge for Japan’s Pharmaceutical Top Twenty”. All of them are part of Catenion’s “Shaping Pharmaceutical Strategy” series that focuses on high-profile issues for the industry.

Markus Thunecke is a founding Partner and the CEO of Catenion who lives in Berlin, Germany. Markus started his consulting career in 1997 at Mercer Management Consulting before joining a strategy consulting boutique, Theron, and setting up Catenion in 2003.

Markus has helped numerous clients around the globe in the pharmaceutical and medical products industries create competitive advantage. In addition to his work on strategy, Markus specialises in developing leading–edge analytical tools and combining them with organisational development capabilities. Markus is the developer of a number of Catenion’s proprietary tools for portfolio management and risk assessment. In recent engagements, Markus has helped clients develop and realign their R&D strategies, review their discovery and development portfolios, and create organisational models that foster innovation.

Markus is a frequent speaker at conferences on R&D strategy and portfolio management.

He holds a PhD in biochemistry from the University of Heidelberg, where he generated transgenic animal models for Alzheimer’s disease. He also has three years of research experience within the CNS field at Schering AG.